First and Only Agent to Achieve Several Key Milestones for Patients with Intermediate-2 and High Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukaemia (AML) with 20 to 30 Percent Bone Marrow Blasts Including:Significantly Extending Survival and Doubling the Two-Year Overall Survival RateAchieving a Transfusion Independence Rate of Greater Than 40 Percent Across These Disease Categories

read more>>

London, UK and Copenhagen, Denmark – GlaxoSmithKline and Genmab A/S announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for Arzerra™ (ofatumumab) for the treatment of chronic lymphocytic leukaemia (CLL).

read more>>

Celgene International Sàrl (Nasdaq:CELG) today announced that the company has received a preliminary positive recommendation from NICE for the use of REVLIMID in the NHS in England and Wales. The recommendation specifies the use of REVLIMID, in combination with dexamethasone, as an option for the treatment of patients with multiple myeloma who have received two or more prior therapies.

read more>>

Galway musicians and DJs will gather in the Black Box Theatre on Saturday February 7 from 6pm for Armada Corazon, a major fundraising show for the Spanish-born, Galway-based musician Luis Asturias.Luis Asturias has been one of the most prominent figures in the Galway music scene since arriving from his native Spain 12 years ago. He has played with many local bands and songwriters, most famously…

read more>>

FJC, a foundation of philanthropic donor-advised funds and the Myeloma Research Foundation are the latest major donors to the "Cure Myeloma Project", an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA.

read more>>

WHITE PLAINS, NY and PRINCETON, NJ – The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc. today announced a partnership to support Phase 2 development of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML).

read more>>

A Miami-Dade firefighter known for her adventurous and giving nature battles to overcome a rare form of leukemia. Now her colleagues are rallying to help her live.''I do not worry about dying. I do feel sad some nights, but when I think about my co-workers, I'm reminded of the fantastic times I have had,'' Catherine Wall said.In September, Wall, 42, was diagnosed with a blood disorder called…

read more>>

CAMBRIDGE, Mass. - Biopure Corporation announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company's oxygen therapeutic Hemopure(R) [hemoglobin glutamer - 250 (bovine)]. In the proposed trial Hemopure would be studied for use in the treatment of life-threatening anemia…

read more>>

SAN FRANCISCO - Eisai Corporation of North America today announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia. The study involved elderly patients with AML, who often have limited options due to comorbidities and are typically considered ineligible for standard induction…

read more>>

Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML

read more>>